ClinicalTrials.gg
RecruitingNCT06981390Updated Nov 19, 2026

Ticagrelor-Based Dual Antiplatelet Therapy Duration in CABG

An interventional study of Ticagrelor + Aspirin for 3 Months (followed by aspirin monotherapy) and Ticagrelor + Aspirin for 6 Months (followed by aspirin monotherapy) in Coronary Artery Disease, Coronary Artery Bypass Grafting and Saphenous Vein, sponsored by Kexiang Liu, MD. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Kexiang Liu, MD · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Nov 19, 2026Now RecruitingSite recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 543 studies in Coronary Artery Disease with a site in China — 176 open to participants now, 210 under way, 6 of them phase 3. Coronary Artery Disease · China.

Planned enrollment
164th of 324
300 · median 307
Started
2026
with 53 others
No phase
210 of 543
71 open now
Primary completion
2027-02
later than 118 of 209 live
Registered
443rd of 543
by date

Among the 543 studies in Coronary Artery Disease with a site in China, this one is the 164th largest by planned enrollment of the 324 interventional ones that give a count, is one of 54 that started in 2026, is one of 210 with no phase, reaches primary completion later than 118 of the 209 other live ones, and was the 443rd registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

176 of the 543 studies in Coronary Artery Disease with a site in China are open now. Recruiting first, the newest first:

170 more — sign in →

All 176 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 543 studies in Coronary Artery Disease with a site in China, or all of them as a file.
02

Study summary

This randomized controlled trial aims to evaluate the impact of different durations of Ticagrelor-based dual antiplatelet therapy (DAPT) on saphenous vein graft (SVG) patency in patients undergoing coronary artery bypass grafting (CABG). A total of 300 patients will be randomly assigned to receive Ticagrelor (90 mg BID) + Aspirin (100 mg QD) for 3 months, 6 months, or 12 months, followed by aspirin monotherapy.The primary outcome is 1-year graft patency, assessed via coronary CT angiography. Secondary outcomes include bleeding events (BARC classification), major adverse cardiovascular and cerebrovascular events (MACCE), and all-cause mortality. The study aims to determine the optimal DAPT duration to balance graft patency benefits and bleeding risks, ultimately guiding postoperative antiplatelet strategies for CABG patients.

Read the detailed description

Coronary artery bypass grafting (CABG) is a widely used revascularization strategy for patients with complex coronary artery disease. However, the long-term patency of saphenous vein grafts (SVGs) remains a significant clinical concern, with graft occlusion being a major contributor to recurrent ischemic events. Dual antiplatelet therapy (DAPT), consisting of Ticagrelor and Aspirin, is commonly used to prevent thrombosis and improve graft patency, yet the optimal duration of DAPT post-CABG remains unclear. This randomized, double-blind, controlled trial aims to assess the effects of different DAPT durations on SVG patency and clinical outcomes in CABG patients. A total of 300 patients undergoing isolated CABG with at least one SVG will be enrolled and randomly assigned (1:1:1) to receive Ticagrelor (90 mg BID) + Aspirin (100 mg QD) for 3 months, 6 months, or 12 months, followed by aspirin monotherapy. The primary outcome of the study is SVG patency at 12 months, assessed via coronary CT angiography, defined as FitzGibbon Grade A (≤50% stenosis). Secondary outcomes include bleeding events , major adverse cardiovascular and cerebrovascular events (MACCE), and all-cause mortality. Patients will be followed at 3, 6, and 12 months postoperatively, undergoing clinical assessments, laboratory tests, and imaging evaluations to monitor graft patency, bleeding complications, and cardiovascular and cerebrovascular events. The study will provide critical data to determine the optimal duration of DAPT to maximize graft patency while minimizing bleeding risks, ultimately guiding personalized antiplatelet strategies in CABG patients.

03

Conditions studied

  • Coronary Artery Disease
  • Coronary Artery Bypass Grafting
  • Saphenous Vein
  • Dual Antiplatelet Therapy
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients 18-80 of age.
  2. Patients undergo planned CABG for the first time with ≥1 SVGs
  3. Patients with written .

Exclusion criteria

Exclusion Criteria:

  1. Patients undergoing concomitant valve surgery (excluding aortic bioprosthesis), aortic surgery, or rhythm surgery during the same session.
  2. Patients undergoing emergency CABG.
  3. Patients with single-vessel coronary artery disease.
  4. Patients with cardiogenic shock or hemodynamic instability.
  5. Patients with sick sinus syndrome, second- or third-degree atrioventricular block.
  6. Patients with for coronary computed tomography angiography (CCTA) or coronary angiography, including contrast media allergy.
  7. Patients requiring antiplatelet therapy other than aspirin or ticagrelor (e.g., clopidogrel, prasugrel) and unable to discontinue such medication after CABG, based on physician or investigator judgment.
  8. Patients on oral anticoagulants before CABG who must continue anticoagulation therapy postoperatively.
  9. Patients with contraindications for ticagrelor or aspirin, including:

    9.1Bleeding diathesis within the past 3 months. 9.2Severe gastrointestinal bleeding within the past year. 9.3Peptic ulcer (even without bleeding) within the past 3 years. 9.4History of intracranial hemorrhage, aspirin allergy, or severe aspirin-induced gastrointestinal reaction.

  10. Patients with a drug-eluting stent (DES) in a coronary or cerebral artery within 6 months before CABG, or a bare-metal stent (BMS) within 1 month before CABG.
  11. Patients with thrombocytopenia (\<100 x 10⁹/L) before CABG.
  12. Patients with severe renal dysfunction requiring dialysis or active liver disease, including unexplained persistent transaminase elevation or transaminase levels >3× the upper normal limit.
  13. Patients using strong inhibitors.
  14. Patients requiring methotrexate and ibuprofen therapy.
  15. Patients with active malignant tumors with an increased risk of bleeding, as determined by the investigator.
  16. Pregnant or breastfeeding women, and those who have given birth within the past 90 days.
  17. Premenopausal women not using adequate . Adequate contraception requires at least two reliable methods, including one barrier method.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
300 participants (estimated)

Study arms

  • Active comparator
    3-Month DAPT Group

    Ticagrelor (90 mg BID) + Aspirin (100 mg QD) for 3 months, followed by aspirin monotherapy

    Drug: Ticagrelor + Aspirin for 3 Months (followed by aspirin monotherapy)

  • Active comparator
    6-Month DAPT Group

    Ticagrelor (90 mg BID) + Aspirin (100 mg QD) for 6 months, followed by aspirin monotherapy

    Drug: Ticagrelor + Aspirin for 6 Months (followed by aspirin monotherapy)

  • Experimental
    12-Month DAPT Group

    Ticagrelor (90 mg BID) + Aspirin (100 mg QD) for 12 months, followed by aspirin monotherapy

    Drug: Ticagrelor + Aspirin for 12 Months (followed by aspirin monotherapy)

Interventions

  • DrugTicagrelor + Aspirin for 3 Months (followed by aspirin monotherapy)

    Ticagrelor (90 mg BID) + Aspirin (100 mg QD) for 3 months, followed by aspirin monotherapy

    Also known as: 3-Month DAPT

  • DrugTicagrelor + Aspirin for 6 Months (followed by aspirin monotherapy)

    Ticagrelor (90 mg BID) + Aspirin (100 mg QD) for 6 months, followed by aspirin monotherapy

    Also known as: 6-Month DAPT

  • DrugTicagrelor + Aspirin for 12 Months (followed by aspirin monotherapy)

    Ticagrelor (90 mg BID) + Aspirin (100 mg QD) for 12 months, followed by aspirin monotherapy

    Also known as: 12-Month DAPT

06

What researchers measure

Primary outcomes

  1. Saphenous Vein Graft (SVG) Patency at 12 Months

    SVG patency will be assessed using coronary CT angiography, defined as FitzGibbon Grade A (≤50% stenosis). The patency rates will be compared among the three groups receiving Ticagrelor-based DAPT for different durations (3 months, 6 months, or 12 months).

    Time frame: 12 months post-CABG

Secondary outcomes

  1. Bleeding Events

    Bleeding events as defined by the BARC classification ≥ 2 at 1 year after CABG.

    Time frame: Up to 12 months post-CABG

  2. MACCE episodes

    MACCE episodes within 1-year after CABG (composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke or revascularization), as defined by the American College of Cardiology and American Heart Association and judged by an independent Clinical Endpoint Committee blinded to treatment allocation

    Time frame: Within 1-year after CABG

  3. All-Cause Mortality

    Death from any cause occurring during the study period.

    Time frame: Up to 12 months post-CABG

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Feb 2027, 9 months after the start.

Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 9 months is below that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2025
First posted
May 20, 2025
StartActual
May 1, 2026
Primary completionEst.
Feb 20, 2027
CompletionEst.
Mar 20, 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 19, 2026
Sites
the Second Hospital of Jilin University is now Recruiting
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Not yet recruiting→Recruiting
    the Second Hospital of Jilin University is now Recruiting
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06981390
Lead sponsor
Kexiang Liu, MD
Responsible party
Kexiang Liu, MD (Principal Investigator, Second Hospital of Jilin University) — Sponsor-investigator
First posted
May 20, 2025
Start date
May 1, 2026
Primary completion
Feb 20, 2027 (estimated)
Completion
Mar 20, 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

kexiang liu
Contact
kxliu64@hotmail.com
17390920328
kexiang liu
study director · Second Hospital of Jilin University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion